Abstract. Tobacco smoke is a major risk factor for lung cancer. Epithelial-mesenchymal transition (EMT) is decisive in cancer invasion and metastasis, and therefore promotes cancer progression. Mitogen-activated protein kinase (MAPK) pathways are implicated in various aspects of cancer development and progression, including the EMT process. The chemopreventive effect of curcumin on carcinogenesis has been reported in vivo and in vitro. The present study investigated tobacco smoke-induced alterations in the MAPK/activator protein-1 (AP-1) pathways, and pulmonary EMT changes in the lungs of mice, and further observed the chemopreventive effect of curcumin. The protein expression levels analyzed by western blot analysis demonstrated that 12 weeks of tobacco smoke exposure activated extracellular-signal-regulated kinase (ERK) 1/2, c-Jun N-terminal kinase (JNK) and p38 MAPK pathways, in addition to AP-1, in the lungs of mice, while reducing the activation of ERK5/MAPK pathways. The results also indicated that the mRNA and protein levels of the epithelial markers E-cadherin and zona occludens-1 were reduced following tobacco smoke exposure. Conversely, the expression levels of mRNA and protein for the mesenchymal markers vimentin and N-cadherin were increased. Curcumin treatment inhibited tobacco smoke-induced MAPK/AP-1 activation, including ERK1/2, JNK and p38 MAPK pathways, and AP-1 proteins, and reversed EMT alterations in lung tissue. The results of the present study provide new insights into the molecular mechanisms of tobacco smoke-associated lung cancer and may open up new avenues in the search for potential therapeutic targets in lung tumorigenesis.
Introduction
Lung cancer is the most common type of cancer worldwide; the incidence and mortality rates of lung cancer are the highest among all human malignant tumors (1, 2) . At present, lung cancer is the leading cause of cancer-associated mortality among men and women in China and western countries. It is estimated that the number of new cases of lung cancer reached 651,053 with a mortality rate of 529,153, in 2011 (3) .
Tobacco smoke has an important role in the initiation and development of lung cancer. It is estimated that ~90% of lung cancer cases are associated with tobacco smoke (4) , including 80% of all female and 90% of all male lung cancer cases (5) . As a complex mixture, tobacco smoke contains >6,000 individual chemical constituents, among which 150 have been reported to exert toxicological effects, including the induction of free radicals and carcinogenic activities (6, 7 ingredients are responsible for the carcinogenic potential of tobacco smoke, including the transformation and progression of cancer. Although progress has been made concerning the molecular mechanisms responsible for tobacco smoke-induced lung cancer development, the molecular pathogenesis requires further investigation. Epithelial-mesenchymal-transition (EMT) is involved in embryonic development and tumorigenesis (8, 9) . EMT is decisive in cancer invasion and metastasis. Evidence has indicated that EMT contributes to tumor progression by allowing cancer cells to avoid apoptosis and cellular senescence (10) . During this process, cells progressively lose expression of membranous epithelial markers and acquire mesenchymal features (11) . Tobacco smoke has been reported to promote EMT (12, 13) . It has been identified that tobacco smoke-induced EMT may regulate the early events in carcinogenesis, including deprivation of cell-cell adhesion and apical-basal polarity, reduced expression of epithelial cadherin and upregulation of cell mobility (13) . However, the potential mechanisms of tobacco smoke-induced EMT remain unclear.
The mitogen activated protein kinase (MAPK) cascade is a crucial signaling cascade involved in the transmission of stress-associated stimuli (14) . This pathway also serves a key role in the development and progression of cancer (15) . The classical MAPK pathway includes extracellular-signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38. Recent studies have reported that EMT may be controlled by ERK1/2, JNKs, p38 and ERK5 (16, 17) . Results from our previous studies have demonstrated that MAPK pathways are involved in tobacco smoke-induced EMT (18) (19) (20) (21) .
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1, 6-hepadiene-3,5-dione] is the principal active component of the plant Curcuma longa. For centuries curcumin has been used widely throughout India and South Asia in Ayurvedic medicine due to its nontoxic and beneficial properties, which include anti-inflammatory, antioxidant, wound healing and antiseptic properties (22) (23) (24) (25) . In addition, evidence has indicated that curcumin exhibits anticancer properties by affecting various biological pathways involved in apoptosis, mutagenesis, cell cycle regulation, oncogene expression, metastasis and angiogenesis (26) (27) (28) . The ability of curcumin to inhibit carcinogenesis has been reported in vivo and in vitro (29) . Our previous studies have demonstrated that tobacco smoke-induced alterations in EMT in the bladder and stomach tissues of mice are effectively attenuated by curcumin (18, 19) . However, to the best of our knowledge, whether curcumin exhibits a protective effect on tobacco smoke-induced lung EMT is yet to be determined.
The present study aimed to investigate the effect of tobacco smoke on the activation of MAPK pathways and EMT in the lung in vivo, and further investigate the protective effects of curcumin against tobacco smoke-exposure. The results confirmed that curcumin exhibits a chemopreventive effect on tobacco smoke-induced lung EMT. Animal and tobacco smoke exposure. A total of 52 male BALB/c mice (4-weeks-old; weight, 18-22 g) were purchased from the Animal Research Center of Nanjing Medical University (Nanjing, China). All mice were allowed one week acclimatize to circumstances prior to experimental exposure. Mice were raised in polypropylene cages at 22±0.5˚C and 40-60% relative humidity with a 12-h light/dark cycle, and water and basal diet were provided ad libitum. All mice procedure protocols were approved by the Animal Care and Welfare Committee of Nanjing Medical University.
Materials and methods

Chemicals
Mice were randomly divided into tobacco smoke-exposure and control groups (n=10/group). The tobacco smoke-exposure group was treated with tobacco smoke for 6 h daily for 12 weeks. The control group animals were exposed to filtered air. Mice in the tobacco smoke group were exposed to tobacco smoke in a smoking apparatus designed by the authors. A smoke machine was used to combust filterless commercial cigarettes (12 mg tar and 1.1 mg nicotine per cigarette, Hongtashan brand; Hongta Group, Yuxi, China) to generate tobacco smoke. The smoke machine pumped the cigarette smoke regularly from burning filterless cigarettes (5 min/cigarette). The target concentration of smoke was delivered to whole-body exposure chambers in total particulate matter of 85 mg/m ) for the tobacco smoke exposure group. Mice were sacrificed at the end of the final tobacco smoke exposure, and the lung tissues were isolated, frozen and stored at -80˚C until analysis.
Curcumin treatment of mice. Doses were selected based on those employed by previous studies involving the treatment of mice with curcumin, which were 50 or 100 mg/kg body weight (BW) per day in animal models (30, 31) . BALB/c mice were randomly assigned into the following four groups (n=8 per group): Filtered air group, in which mice were exposed to filtered air and under a controlled diet; a tobacco smoke-exposed group, in which mice were exposed to tobacco smoke and under a controlled diet; tobacco smoke + curcumin 50 mg group, in which mice were exposed to tobacco smoke and under a controlled diet supplemented with curcumin at a dose of 50 mg/kg BW/day; and tobacco smoke + curcumin 100 mg group, in which mice were exposed to tobacco smoke and under a controlled diet supplemented with curcumin at a dose of 100 mg/kg BW/day. The mice were exposed to filtered air or tobacco smoke at a target concentration of 85 mg/m 3 total particulate matter for 6 h daily for 12 weeks. Dietary consumption levels and body weight were measured and recorded every 3 days to determine the administration dosages of curcumin. The diets were prepared weekly for each group. At the end of the exposure, mice were sacrificed and the lung tissues were frozen and stored at-80˚C until analysis.
Western blot analysis. Western blot analyses were performed following standard procedures. Briefly, lung tissues were lysed (lysate buffer, 5 mmol/l EDTA; 50 mmol/l Tris pH 7.5, 1% sodium dodecyl sulfate (SDS), 10 µg/ml aprotinin, 1% sodium deoxycholate, 1% NP-40, 1% Triton-X 100, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin) and the lysate supernatants were obtained by centrifugation at 12,000 x g for 20 min at 4˚C and the pellets were discarded. A BCA Protein assay kit (Pierce; Thermo Fisher Scientific, Inc.) was used to measure protein concentrations. Electrophoresis was performed to fractionate 50 µg proteins by 7.5-10% SDS-PAGE. Subsequently, proteins were transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). Following blocking with 5% non-fat milk for 1 h at room temperature, membranes were incubated with primary antibodies overnight at 4˚C, followed by incubation with horseradish peroxidase-conjugated secondary antibody (cat. no. 00001-2; 1:5,000) from Biogot Technology Co., Ltd. (Nanjing, China) for 1 h at room temperature. The membranes were developed with SignalFire Elite ECL Reagent (Cell Signaling Technology, Inc.). GAPDH served as the loading control. ImageJ k 1.45 (National Institutes of Health, Bethesda, MD, USA) was used to perform densitometric analysis on protein bands.
RT-qPCR analysis. Total RNA was extracted from the mouse lung tissues using RNAiso Plus (Takara Bio, Inc., Otsu, Japan), according to the manufacturer's protocol. Subsequently, 2 µg purified total RNA was reverse transcribed to cDNA using PrimeScript RT Master mix (Takara Bio, Inc.) according to the manufacturer's protocol. The RT reaction was performed as follows: 37˚C 15 min, 85˚C 5 sec, and hold at 4˚C, using AMV Reverse Transcriptase (Promega Corporation, Madison, WI, USA). qPCR was performed according to the manufacturer's protocol: Initial denaturation at 95˚C for 30 sec, followed by 40 cycles of 95˚C for 5 sec, 60˚C for 30 sec, 72˚C for 30 sec using the SYBR ® Premix Ex Taq™ II (Takara Bio, Inc.) and an ABI prism 7300 system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers (Invitrogen; Thermo Fisher Scientific, Inc.) used were as follows: E-cadherin forward, 5'-TCG ACA CCC GAT TCA AAG TGG -3' and reverse, 5'-TTC CAG AAA CGG AGG CCT GAT -3'; ZO-1 forward, 5'-GCA GCC ACA ACC AAT TCA TAG -3' and reverse, 5'-GCA GAC GAT GTT CAT AGT TTC-3'; vimentin forward, 5'-CCT TGA CAT TGA GAT TGC CA-3' and reverse, 5'-GTA TCA ACC AGA GGG AGT GA-3'; N-cadherin forward, 5'-ATC AAG TGC CAT TAG CCA AG-3' and reverse, 5'-CTG AGC AGT GAA TGT TG T CA-3'; GAPDH forward, 5'-GCT GCC CAA CGC ACC GA A TA-3' and reverse, 5'-GAG TCA ACG GAT TTG GTC GT-3'. The specificity of the PCR products was confirmed using melting curve analysis. Relative gene expression levels, normalized to GAPDH expression, were calculated by a comparative threshold cycle (Cq) method using the formula 2 -(ΔΔCq) (32) . Each sample was performed in triplicate.
Statistical analysis. Statistical differences were analyzed using one-way analysis of variance for comparison of statistical differences among multiple groups and the Fisher's least significant difference test. Unpaired Student's t-test was also used for comparisons between two groups. SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA) was used to perform statistical analysis. Data are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.
Results
Tobacco smoke induces EMT alterations in lung tissues of mice.
Tobacco smoke is a major risk factor for lung cancer.
EMT has important functions in various types of cancer, including lung cancer, and tobacco smoke-induced EMT is implicated in tobacco smoke-associated malignant transformations. To determine whether alterations in EMT were induced by tobacco smoke in an animal model, mice were exposed to tobacco smoke for 12 weeks, and the expression of the epithelial markers E-cadherin and ZO-1, and the mesenchymal markers vimentin and N-cadherin, in lung tissues was examined. Tobacco smoke exposure led to reduced E-cadherin and ZO-1 mRNA levels in mice lungs, and the mRNA expression of vimentin and N-cadherin was increased, compared with the filtered air-treated group, as determined by RT-qPCR (Fig. 1A) . Western blot analysis further revealed that tobacco smoke exposure also led to similar effects at the protein level, with downregulated E-cadherin and ZO-1 protein expression levels, and upregulated N-cadherin and vimentin protein expression levels compared with the filtered air-treated group (Fig. 1B and C) .
Tobacco smoke activates pulmonary MAPK/AP-1 pathways in mice.
The expression levels of p-ERK1/2, p-JNK, p-p38 and p-ERK5 were also measured to establish whether the observed tobacco smoke-induced pulmonary EMT alterations are associated with changes in MAPK activation. The results demonstrated that tobacco smoke increased the activation of ERK1/2, JNK and p38 pathways, while it suppressed the ERK5 MAPK pathway ( Fig. 2A) . Additionally, tobacco smoke exposure upregulated the levels of p-c-Fos, p-c-Jun and Fra-2, which are indicators of the AP-1 activation status (Fig. 2B) .
Curcumin reverses tobacco smoke-induced EMT alterations in the lungs of mice.
To investigate whether curcumin may reverse tobacco smoke-mediated EMT in the mouse lung, mice were treated with curcumin (50 or 100 mg/kg BW) and exposed to tobacco smoke for 12 weeks. Tobacco smoke-induced alterations in the mRNA and protein expression EMT markers were subsequently investigated. As expected, the results demonstrated that curcumin, particularly 100 mg/kg BW curcumin, treatment attenuated the tobacco smoke-induced decreases in E-cadherin and ZO-1 expression, and increases in vimentin and N-cadherin expression. These results indicate that curcumin reversed tobacco smoke-induced alterations in pulmonary EMT in vivo (Fig. 3) . MAPK/AP-1 activation following curcumin treatment were examined. Western blot analysis revealed that curcumin (100 mg/kg BW) suppressed tobacco smoke-induced ERK1/2, p38 and JNK activation, and increased ERK5 activation in the lung tissues of mice exposed to tobacco smoke (Fig. 4A) .
The results also demonstrated that treatment with 100 mg/kg BW curcumin significantly decreased tobacco smoke-induced AP-1 activation, as indicated by reduced expression of p-c-Fos, p-c-Jun and Fra-2 compared with the tobacco smoke-treated group without curcumin treatment (Fig. 4B) .
Discussion
Lung cancer is the leading cause of cancer-associated mortality globally. Studies have confirmed the association between the occurrence of lung cancer and tobacco smoke (33, 34) . As a major contributor to lung cancer, tobacco smoke promotes the initiation and progression of lung cancer. However, further investigation of the mechanisms involved in the initiation and development of lung cancer induced by tobacco smoke is required. The present study demonstrated that EMT alterations were induced by tobacco smoke in the lungs of mice. It further revealed that the activation of MAPK pathways was implicated in tobacco smoke-induced lung EMT, in addition to AP-1 activation. Furthermore, the results indicated that curcumin treatment prevented tobacco smoke-induced lung EMT changes and MAPK/AP-1 activation in vivo.
EMT serves an important role in cancer initiation and development. The exposure of cells to carcinogens has been reported to induce EMT during transformation and tumor formation (35) (36) (37) (38) (39) , indicating that EMT, by promoting cell malignancy transformation, may be associated with the initiation of tumorigenesis. The results of the present study were consistent with these reports, as they demonstrated that, following exposure to tobacco smoke for 12 weeks, tobacco alterations in EMT were observed in the lungs of mice. Tobacco smoke exposure decreased the expression of the epithelial markers E-cadherin and ZO-1, and increased the expression of the mesenchymal markers vimentin and N-cadherin. These results indicate that tobacco smoke may induce lung EMT in vivo.
EMT alterations are associated with various cell signaling pathways. MAPK pathways are reported to promote the initiation and progression of cancer, and are therefore important in the tumorigenic process (40) . Studies have demonstrated that p38, ERK1/2 and JNK promote EMT (16, 17, 41) . However, the role of ERK5 in EMT regulation has not been well characterized. The present study identified that tobacco smoke upregulated p38, ERK1/2 and JNK, thus inducing lung EMT in vivo. However, it was also demonstrated that tobacco smoke downregulated ERK5 activation, which was consistent with our previous findings (20, 21) . Furthermore, the present study also demonstrated that tobacco smoke-induced EMT was associated with increased activation of AP-1. These results indicate that tobacco smoke-induced lung EMT may be associated with MAPK/AP-1 activation.
Curcumin is a turmeric-derived active component that has been widely used in medicine in India and Southeast Asia (42) . It has been used as a chemopreventive agent against a number of tumors due to its anticancer functions. The safety and anticancer activities of curcumin have been reported in various cancers (43, 44) . In the present study, BALB/c mice were treated with curcumin at 50 and 100 mg/kg BW/day. These concentrations were selected as they proved to be efficient in other animal studies (31, 45) . These doses are equivalent to a human dose of 3-6 g/day per adult (46) . Following curcumin and tobacco smoke treatment for 12 weeks, changes in the mRNA and protein expression of EMT markers were examined, and the results indicated that the expression of the epithelial markers ZO-1 and E-cadherin was downregulated, while the expression of the mesenchymal markers N-cadherin and vimentin was upregulated, in mice treated with tobacco smoke compared with those treated with filtered air. Furthermore, curcumin (100 mg/kg BW/day) markedly attenuated tobacco smoke-induced EMT alterations in the lungs of mice. It was also demonstrated that treatment with curcumin at 100 mg/kg BW suppressed tobacco smoke-induced activation of JNK, ERK1/2 and p38 MAPK pathways, in addition to AP-1 activation. Thus, the results of the present study indicate that the curcumin-mediated protective effect against tobacco smoke-induced pulmonary EMT changes may occur via MAPK/AP-1 pathways.
In conclusion, the present study demonstrated that curcumin treatment effectively attenuated tobacco smoke-induced MAPK activation and EMT changes in lung tissue. These data may provide novel insights into the molecular pathogenesis and chemoprevention of tobacco smoke-associated lung cancer.
